

Response

2
The Department may, at its discretion, publish part or all of the information provided in your submission on the Department's website or in related documents. If information from your submission is published, the Department may identify you and/or your organisation as the author of the submission. All personal contact details will be removed prior to publishing.

Yes, I consent to my identified submission being published

3

What is your name?

Georgie McKenzie

7

Please select the type of individual(s) or organisation(s) you represent. Please select all that apply. - Selected Choice

Patient or consumer (or representative organisation), Clinician (or representative organisation)

8.1

What is the name of your organisation? - My organisation is called: - Text

Ovarian Cancer Australia

9

Are you making feedback on behalf of your organisation?

Your organisation

13

Please select which chapter/s you would like to provide feedback on. You may provide feedback on as many or few chapters as you wish.

1. Transparency, communication, and stakeholder involvement in HTA, 2. Health technology funding and assessment pathways, 3. Methods for HTA for Australian government subsidy (technical methods), 4. Health technology funding and purchasing approaches and managing uncertainty, 5. Futureproofing Australia's systems and processes

14

Please select the topics within the chapter(s) you would like to provide feedback on. 1. Transparency, communication and stakeholder involvement in HTA

1.1. Transparency and communication of HTA pathways, processes and decisions, 1.2. Consumer, clinician and other stakeholder engagement and consideration in HTA, 1.3. First Nations people involvement and consideration in HTA

15

Please select the topics within the chapter(s) you would like to provide feedback on. 2. Health technology funding and assessment pathways

2.1. Streamlining and aligning HTA pathways and advisory committees

18

Please select the topics within the chapter(s) you would like to provide feedback on. 5. Futureproofing our systems and processes

5.1. Proactively addressing areas of unmet clinical need and gaps in the PBS, 5.2. Establishment of horizon scanning programs to address specific informational needs within HTA and the health system

21

Taking all Options within this section: 1.1. Transparency, communication and stakeholder involvement in HTA into account.

Overall, to what extent could the options (if implemented) address the issues that relate to them?

Mostly address the issue(s)

22

If you would like to expand on your answer above you can do so below:

See attached document

23.1

If implemented, overall would these Options have a positive or negative impact on you ((your organisation)? - Publish plain language summaries

Very positive

23.2

If implemented, overall would these Options have a positive or negative impact on you ((your organisation)? - Improvements to the HTA webpage including development of a dashboard

Very positive

25

If you would like to expand on your answer above you can do so below -Publish plain language summaries

See attached document

26

If you would like to expand on your answer above you can do so below -Improvements to the HTA webpage including development of a dashboard

See attached document

27

Taking all Options within this section: 1.2. Consumer, clinician and other stakeholder engagement and consideration in HTA into account.

Overall, to what extent could the options (if implemented) address the issues that relate to them?

Mostly address the issue(s)

28

If you would like to expand on your answer above you can do so below:

See attached document

29.1

If implemented, overall would these Options have a positive or negative impact on you ((your organisation)? - Develop an engagement framework

Very positive

29.2

If implemented, overall would these Options have a positive or negative impact on you ((your organisation)? - Strengthen consumer evidence

Very positive

31

If you would like to expand on your answer above you can do so below -Develop an engagement framework

See attached document

32

If you would like to expand on your answer above you can do so below -Strengthen consumer evidence

See attached document

33

Taking all Options within this section: 1.3. First Nations people involvement and consideration in HTA into account.

Overall, to what extent could the options (if implemented) address the issues that relate to them?

Mostly address the issue(s)

34

If you would like to expand on your answer above you can do so below:

See attached document

35.1

If implemented, overall would these Options have a positive or negative impact on you ((your organisation)? - First Nations peoples partnership in decision making

Very positive

35.2

If implemented, overall would these Options have a positive or negative impact on you ((your organisation)? - Dedicated resource for HTA submissions and education

Very positive

37

If you would like to expand on your answer above you can do so below -First Nations peoples partnership in decision making

See attached document

38

If you would like to expand on your answer above you can do so below -Dedicated resource for HTA submissions and education

See attached document

46

Taking all Options within this section: 2.1. Streamlining and aligning HTA pathways and advisory committees into account.

Overall, to what extent could the options (if implemented) address the issues that relate to them?

Mostly address the issue(s)

47

If you would like to expand on your answer above you can do so below:

See attached document

48.1

If implemented, overall would these Options have a positive or negative impact on you ((your organisation)? - Pathway for drugs for ultra-rare diseases (Life Saving Drugs Program (LSDP))

Positive

48.2

If implemented, overall would these Options have a positive or negative impact on you ((your organisation)? - Vaccine pathway

Neutral

48.3

If implemented, overall would these Options have a positive or negative impact on you ((your organisation)? - Expanding role of PBAC

Very positive

48.4

If implemented, overall would these Options have a positive or negative impact on you ((your organisation)? - Unified HTA pathway for all health technologies with Commonwealth funding

Very positive

50

Pathway for drugs for ultra-rare diseases (Life Saving Drugs Program (LSDP))

See attached document

60

If you would like to expand on your answer above you can do so below -Vaccine pathway

See attached document

61

If you would like to expand on your answer above you can do so below -Expanding role of PBAC

See attached document

62

If you would like to expand on your answer above you can do so below -Unified HTA pathway for all health technologies with Commonwealth funding

See attached document

131

Taking all Options within this section: 5.1. Proactively addressing areas of unmet clinical need and gaps in the PBS into account.

Overall, to what extent could the options (if implemented) address the issues that relate to them?

Mostly address the issue(s)

132

If you would like to expand on your answer above you can do so below:

See attached document

133.1

If implemented, overall would these Options have a positive or negative impact on you (/your organisation)? - Development of a priority list

Very positive

133.2

If implemented, overall would these Options have a positive or negative impact on you (/your organisation)? - Identifying therapies to meet priority list (horizon scanning)

Very positive

133.3

If implemented, overall would these Options have a positive or negative impact on you (/your organisation)? - Early assessment and prioritisation of potentially promising therapies

Very positive

133.4

If implemented, overall would these Options have a positive or negative impact on you (/your organisation)? - Proactive submission invitation and incentivisation

Very positive

133.5

If implemented, overall would these Options have a positive or negative impact on you (/your organisation)? - Early PICO scoping

Very positive